{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T01:25:08Z","timestamp":1771550708901,"version":"3.50.1"},"reference-count":39,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AO"],"abstract":"<jats:p>Background: Significant progress has been made in the management of metastatic NSCLC (mNSCLC). Our study investigated characteristics, treatment patterns, and outcomes in this patient population and subgroups based on histology and PD-L1 status.\nMethods: We conducted a retrospective analysis of electronic health records of patients with mNSCLC 1\/2019-8\/2023 at HUS, Helsinki University Hospital, Finland. Patient characteristics, treatment, and outcomes were analyzed.\nResults: We identified 646 patients with mNSCLC, including those metastatic at diagnosis and whose cancer later progressed to metastatic, who received systemic therapy. Median age was 70 years (interquartile range [IQR]: 62\u201375). Squamous cell carcinoma (SqC) presented 19% of patients, adenocarcinoma 68%, and other non-SqC 13%. Amongst the non-SqC patients 53% were female, whereas only 32% of SqC patients were female. Treatment evolved considerably, with increased use of immuno-oncology (IO) and tyrosine kinase inhibitor (TKI) therapies. Median overall survival was 8 months (confidence interval [CI] 95%: 6\u20139) for those treated with chemotherapy alone, 12 months (CI 95%: 7\u201318) for those treated with IO therapy, 14 months (CI 95%: 11\u201315) for those treated with IO + chemotherapy, and 24 months (CI 95%: 16\u201338) for those treated with TKIs.\nInterpretation: Our study reports real-world management of patients with mNSCLC and evolving treatment patterns in clinical practice from the first years of IO treatment availability. As we continue to monitor more recent data, the proportion receiving chemotherapy alone is anticipated to continue decreasing. It is crucial to assess current outcomes in NSCLC to target resources correctly and improve prognosis.<\/jats:p>","DOI":"10.2340\/1651-226x.2025.44254","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T05:46:44Z","timestamp":1765864004000},"page":"1664-1671","source":"Crossref","is-referenced-by-count":1,"title":["Metastatic NSCLC patients in the real world in Finland"],"prefix":"10.2340","volume":"64","author":[{"given":"Heikki","family":"Ekroos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8260-3356","authenticated-orcid":false,"given":"Olivia","family":"H\u00f6ls\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Kreutzman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lila","family":"Nikkola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5750-6120","authenticated-orcid":false,"given":"Johanna","family":"Vikkula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7707-2411","authenticated-orcid":false,"given":"Riikka","family":"Mattila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aija","family":"Knuuttila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"135720","unstructured":"Malila N, Pitk\u00e4niemi J, Hermi\u00f6 E, Johansson S, Sepp\u00e4 K, Toikkanen S. Keuhkosy\u00f6p\u00e4 Suomessa (Lung cancer in Finland). Helsinki: Cancer Society of Finland; 2024. [cited August 8, 2025]. Available from: https:\/\/syoparekisteri.fi\/assets\/files\/2024\/12\/Keuhkosyopa_Suomessa.pdf"},{"key":"135721","unstructured":"Lar\u00f8nningen S, Arvidsson G, Bray F, Dahl-Olsen E, Engholm G, Ervik M, et al. NORDCAN: cancer incidence, mortality, prevalence and survival in the Nordic Countries, Version 9.5 (19.06.2025). [Internet]. Association of the Nordic Cancer Registries. Cancer Registry of Norway. [cited 2025 Oct 9]. Available from: https:\/\/nordcan.iarc.fr\/"},{"key":"135722","unstructured":"Dansk Lunge Cancer Gruppe \/ Register. Dansk Lunge Cancer Register \u00c5rsrapport 2022. 2023 Jun. Report No.: 2022. [cited August 22, 2025]. Available from: https:\/\/www.lungecancer.dk\/wp-content\/uploads\/2023\/06\/%C3%85rsrapport-2022-DLCR-offentlig.pdf"},{"key":"135723","doi-asserted-by":"crossref","unstructured":"Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, et al. Intra-tumor heterogeneity in localized lung adenocarcinomas delineated by multi-region sequencing. Science. 2014 Oct 10;346(6206):256\u20139.","DOI":"10.1126\/science.1256930"},{"key":"135724","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1126\/science.1256930","DOI":"10.1126\/science.1256930"},{"key":"135725","doi-asserted-by":"crossref","unstructured":"Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018 Jan;553(7689):446\u201354.","DOI":"10.1038\/nature25183"},{"key":"135726","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/nature25183","DOI":"10.1038\/nature25183"},{"key":"135727","unstructured":"Loponen H, Paajanen J, Vihervaara V, Yl\u00e4-Viteli S, Tamminen K, Torvinen S, et al. Treatment patterns and outcomes in a cohort of Finnish NSCLC patients with ALK rearrangement reflect rapid evolution in treatment practices. Int J Clin Exp Med Sci. 2021 Dec 24;7(6):200."},{"key":"135728","doi-asserted-by":"crossref","unstructured":"Leskel\u00e4 RL, Peltonen E, Haavisto I, Herse F, Korhonen S, Nolvi K, et al. Trends in treatment of non-small cell lung cancer in Finland 2014\u20132019. Acta Oncol. 2022 May 4;61(5):641\u20138.","DOI":"10.1080\/0284186X.2022.2042474"},{"key":"135729","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/0284186X.2022.2042474","DOI":"10.1080\/0284186X.2022.2042474"},{"key":"135730","doi-asserted-by":"crossref","unstructured":"Anttalainen A, Pietarinen P, Tuominen S, Mattila R, Mutka A, Knuuttila A. Real-world evidence study of patients with KRAS-mutated NSCLC in Finland. Curr Oncol. 2024 May 11;31(5):2700\u201312.","DOI":"10.3390\/curroncol31050205"},{"key":"135731","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/curroncol31050205","DOI":"10.3390\/curroncol31050205"},{"key":"135732","doi-asserted-by":"crossref","unstructured":"Paakkola NM, Jekunen A, Sihvo E, Johansson M, Anders\u00e9n H. Area-based disparities in non-small-cell lung cancer survival. Acta Oncol. 2024 Apr 9;63:27507.","DOI":"10.2340\/1651-226X.2024.27507"},{"key":"135733","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/1651-226X.2024.27507","DOI":"10.2340\/1651-226X.2024.27507"},{"key":"135734","doi-asserted-by":"crossref","unstructured":"Manninen O, Puuniemi L, Iivanainen S, Arffman M, Kaarteenaho R, Koivunen JP. Treatment outcomes of non-small cell lung cancers treated with EGFR tyrosine kinase inhibitors: a real-world cohort study. Acta Oncol. 2023 Dec 2;62(12):1854\u201361.","DOI":"10.1080\/0284186X.2023.2274481"},{"key":"135735","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/0284186X.2023.2274481","DOI":"10.1080\/0284186X.2023.2274481"},{"key":"135736","doi-asserted-by":"crossref","unstructured":"Kuusisalo S, Tikkanen A, Lappi-Blanco E, V\u00e4is\u00e4nen T, Knuuttila A, Tiainen S, et al. The prognostic and predictive roles of plasma C-reactive protein and PD-L1 in non-small cell lung cancer. Cancer Med. 2023 Aug;12(15):16087\u201397.","DOI":"10.1002\/cam4.6262"},{"key":"135737","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/cam4.6262","DOI":"10.1002\/cam4.6262"},{"key":"135738","doi-asserted-by":"crossref","unstructured":"Manninen O, Iivanainen S, Arffman M, Koivunen JP. Non-small cell lung cancer treated with epidermal growth factor receptor inhibitors: the effect of concurrent medications on patient outcomes. Oncology. 2025;103(10):907\u2013920.","DOI":"10.1159\/000543163"},{"key":"135739","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000543163","DOI":"10.1159\/000543163"},{"key":"135740","doi-asserted-by":"crossref","unstructured":"Kim K, Sweeting M, Wilking N, J\u00f6nsson LM. Cost of treatment of metastatic non-small lung cancer in Sweden, 2011\u20132023. Acta Oncol. 2025 Oct 26;64:1473\u201381.","DOI":"10.2340\/1651-226X.2025.44650"},{"key":"135741","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/1651-226X.2025.44650","DOI":"10.2340\/1651-226X.2025.44650"},{"key":"135742","unstructured":"Finnish Cancer Center FICAN, Finnish Lung Cancer Group. Finnish national treatment guideline for lung cancer [Keuhkosy\u00f6v\u00e4n kansallinen hoitosuositus]. Helsinki: Finnish Cancer Center FICAN, Finnish Lung Cancer Group; 2023."},{"key":"135743","doi-asserted-by":"crossref","unstructured":"Simeone JC, Nordstrom BL, Patel K, Klein AB. Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting. Future Oncol. 2019 Oct 31;15(30):3491\u2013502.","DOI":"10.2217\/fon-2019-0348"},{"key":"135744","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2217\/fon-2019-0348","DOI":"10.2217\/fon-2019-0348"},{"key":"135745","doi-asserted-by":"crossref","unstructured":"Lester J, Escriu C, Khan S, Hudson E, Mansy T, Conn A, et al. 1379P Real-world (RW) clinical outcomes of patients with metastatic non-small cell lung cancer (mNSCLC) in the United Kingdom. Ann Oncol. 2020 Sep;31:S878\u20139.","DOI":"10.1016\/j.annonc.2020.08.1693"},{"key":"135746","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.annonc.2020.08.1693","DOI":"10.1016\/j.annonc.2020.08.1693"},{"key":"135747","doi-asserted-by":"crossref","unstructured":"Ahn BC, Pyo KH, Xin CF, Jung D, Shim HS, Lee CY, et al. Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice. J Cancer Res Clin Oncol. 2019 Jun;145(6):1613\u201323.","DOI":"10.1007\/s00432-019-02899-y"},{"key":"135748","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00432-019-02899-y","DOI":"10.1007\/s00432-019-02899-y"},{"key":"135749","doi-asserted-by":"crossref","unstructured":"Garassino MC, Gadgeel S, Speranza G, Felip E, Esteban E, D\u00f3mine M, et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous non\u2013small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncol. 2023 Apr 10;41(11):1992\u20138.","DOI":"10.1200\/JCO.22.01989"},{"key":"135750","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.22.01989","DOI":"10.1200\/JCO.22.01989"},{"key":"135751","doi-asserted-by":"crossref","unstructured":"Novello S, Kowalski DM, Luft A, G\u00fcm\u00fc\u015f M, Vicente D, Mazi\u00e8res J, et al. Pembrolizumab plus chemotherapy in squamous non\u2013small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study. J Clin Oncol. 2023 Apr 10;41(11):1999\u20132006.","DOI":"10.1200\/JCO.22.01990"},{"key":"135752","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.22.01990","DOI":"10.1200\/JCO.22.01990"},{"key":"135753","doi-asserted-by":"crossref","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with Osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020 Jan 2;382(1):41\u201350.","DOI":"10.1056\/NEJMoa1913662"},{"key":"135754","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1913662","DOI":"10.1056\/NEJMoa1913662"},{"key":"135755","doi-asserted-by":"crossref","unstructured":"Wagenius G, Vikstr\u00f6m A, Berglund A, Salomonsson S, Bencina G, Hu X, et al. Long-term real-world outcomes of first-line immunotherapy in non-small cell lung cancer \u2013 a population-based cohort study in Sweden. Acta Oncol. 2025 Mar 17;64:415\u201322.","DOI":"10.2340\/1651-226X.2025.42746"},{"key":"135756","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/1651-226X.2025.42746","DOI":"10.2340\/1651-226X.2025.42746"},{"key":"135757","doi-asserted-by":"crossref","unstructured":"B\u00f8r\u00f8 S, Thoresen S, Helland \u00c5. Improvements in survival for patients with stage IV adenocarcinoma in the lung, diagnosed between 2010\u20132020 \u2013 a population-based registry study from Norway. Front Oncol. 2022;12:1017902.","DOI":"10.3389\/fonc.2022.1017902"},{"key":"135758","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fonc.2022.1017902","DOI":"10.3389\/fonc.2022.1017902"}],"container-title":["Acta Oncologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/44254\/52291","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/44254\/52291","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T05:46:49Z","timestamp":1765864009000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/44254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":39,"URL":"https:\/\/doi.org\/10.2340\/1651-226x.2025.44254","relation":{},"ISSN":["1651-226X"],"issn-type":[{"value":"1651-226X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]}}}